In recent years, medicine has made significant progress in the treatment of Type 1 Diabetes, offering new options that make blood glucose control easier and more efficient. These advances have helped millions of people live better with the condition.
One of the most important innovations was the development of ultrafast acting insulins. These insulins, such as Fiasp and Lyumjev, begin to act within a few minutes, allowing a more precise control of blood glucose immediately after meals. This helps avoid the glucose spikes that occur shortly after eating food, providing more flexibility on a daily basis.
These insulins are especially useful for people with more hectic routines, who need quick and efficient control without having to wait long periods after application.
Another major breakthrough was the development of continuous glucose monitoring (CGM). These devices allow the person to monitor their glucose levels in real time, without the need to prick the finger several times a day. The CGM sensors are applied under the skin and provide constant glucose readings.
CGM helps identify patterns, such as unexpected glucose spikes or drops, and allows the person to adjust their treatment proactively. In addition, many of these devices can be connected to smartphones, making it easier to control and record measurements.
One of the most anticipated advances in the treatment of Type 1 Diabetes It is the development of artificial pancreas. This system combines the CGM with an insulin pump that automatically adjusts insulin doses based on glucose levels monitored in real time. This system allows for much more precise control and reduces the need for frequent manual interventions.
The artificial pancreas is still under development, but clinical trials have shown promising results, and many experts believe it could be a major revolution in treatment.
Another growing area of research is immunomodulation, which seeks to prevent the immune system from attacking pancreatic beta cells. Although not yet available for general treatment, this approach aims to protect the remaining beta cells in the first few years after the diagnosis of Type 1 Diabetes.
Combined with traditional treatments, these new options offer more hope and quality of life for people with Type 1 Diabetes.
